Stock Research: Atea Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Atea Pharmaceuticals

NasdaqGS:AVIR US04683R1068
37
  • Value
    99
  • Growth
    21
  • Safety
    Safety
    10
  • Combined
    41
  • Sentiment
    49
  • 360° View
    360° View
    37
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock Atea Pharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Atea Pharmaceuticals. The only rank that is above average is the consolidated Safety Rank at 99, which means that the company has a financing structure that is safer than those of 99% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 10, which means that the share price of Atea Pharmaceuticals is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 21, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 49, which means that professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
10 33 38 23
Growth
21 13 33 35
Safety
Safety
99 99 51 51
Sentiment
49 14 57 64
360° View
360° View
37 37 6 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
81 7 1 15
Opinions Change
50 50 83 50
Pro Holdings
n/a 8 39 72
Market Pulse
42 55 74 74
Sentiment
49 14 57 64
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
10 33 38 23
Growth
21 13 33 35
Safety Safety
99 99 51 51
Combined
41 41 94 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
89 89 89 45
Price vs. Earnings (P/E)
1 3 5 6
Price vs. Book (P/B)
77 88 89 77
Dividend Yield
1 1 1 1
Value
10 33 38 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 1 1 3
Profit Growth
60 14 29 94
Capital Growth
3 18 100 83
Stock Returns
39 31 29 3
Growth
21 13 33 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
99 98 99 95
Liquidity
1 1 69 69
Safety Safety
99 99 51 51

Similar Stocks

Discover high‑ranked alternatives to Atea Pharmaceuticals and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.